About Curatis
Curatis is a specialty pharmaceutical company based in Switzerland.
“We focus on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases.
Curatis is engaged in two business areas:
Distribution business for orphan disease and specialty care medicines
Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. Curatis has exclusive distribution rights for more than 30 different drugs in Switzerland – many of them orphan disease and specialty disease medicines. This underlines Curatis’ position in the Swiss orphan drug market.
Curatis has set the goal of significantly increasing the number of third-party drugs under contract in Switzerland. In addition, Curatis aims to secure distribution rights for drugs in major European markets such as Germany, France, the UK, and Italy, reflecting a clear vision for growth and market expansion. In the medium to long term, Curatis expects to launch its own products if its development projects gain regulatory approval. Curatis expects this expansion strategy to be supported by the increased visibility and funding opportunities associated with becoming a part of a publicly listed group.
Development business for orphan and specialty care disease medicines
Curatis has a promising pipeline of novel speciality care and orphan drugs.
Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization.
All of Curatis’ development projects have been selected in line with this strategy:
- C-PTBE-01 for the treatment of peritumoral brain edema in pediatric patients – next development step: pivotal clinical study
- C-AM-01 for the prevention of severe migraine with aura – next development step: clinical phase IIb study
- C-MOH-01 for the treatment and prevention of medication overuse headache – next development step: clinical phase IIb study
- KIN001 for the treatment of rare inflammatory and fibrotic diseases (e.g. Idiopathic Pulmonary Fibrosis) – next development step: clinical proof-of-concept
Board of Directors
Dr. Marian Borovsky, Chairman, Non-Executive Member of the Board of Directors
As Group General Counsel and a member of the Executive Committee, led Actelion’s legal department for 17 years from its startup phase until its acquisition by Johnson & Johnson in 2017. Thereafter, held interim positions as Group General Counsel/Chief Legal Officer with Idorsia Pharmaceuticals AG (March – October 2022) and at Swiss Rockets AG/Rocketvax AG (May – July 2021).
Günter Graubach, Founder & Executive Member of the Board of Directors, Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012-April 2024) and Curatis’ Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a “Maîtrise Administration Économique et Sociale” from the University of Lyon, France and a “lic.oec.int” in International Economic Relations from the University of Constance, Germany.
Dr. Roland Rutschmann, Executive Member of the Board of Directors, Chief Executive Officer (CEO)
Board member of Curatis AG and former Chief Executive Officer of Curatis (2012-2019). Previously he held positions as Vice President/General Manager at Orphan Europe in Paris France and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Mr. Rutschmann also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Mr. Rutschmann holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.
Dr. Silvio Inderbitzin, non-executive member of the Board of Directors
Dr. Silvio Inderbitzin is a member of the Board of Directors and shareholder of Curatis. Dr. Inderbitzin has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his origin in pharmaceutical manufacturing, he also served as Head of Quality Assurance and was responsible for product release as a Qualified Person at Spirig Pharma AG. He was later elected to the position of Technical Director of Spirig Pharma AG and served in the Corporate Management Team, ultimately joining the board of directors and becoming co-owner of the privately held 450 employee company. Prior to the successful sale of the Spirig Pharma AG, he served as CEO and was responsible for its foreign subsidiaries. He is an active investor and board member of several life science and MedTech companies as well as startups. Dr. Inderbitzin studied pharmacy at the University of Berne, holds a Ph.D. in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.
Executive Management
Dr. Roland Rutschmann, Executive Member of the Board of Directors, Chief Executive Officer (CEO)
Board member of Curatis AG and former Chief Executive Officer of Curatis (2012-2019). Previously he held positions as Vice President/General Manager at Orphan Europe in Paris France and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Mr. Rutschmann also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Mr. Rutschmann holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.
Günter Graubach, Founder & Executive Member of the Board of Directors, Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012-April 2024) and Curatis’ Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a “Maîtrise Administration Économique et Sociale” from the University of Lyon, France and a “lic.oec.int” in International Economic Relations from the University of Constance, Germany.
François Bersier, Chief Operating Officer (COO)
Former Chief Executive Officer at Curatis AG (2019-Arpil 2024). Previously General Manager at Alexion Pharma International (GmbH), held various commercial & marketing management lead positions at Roche Pharma, Sanofi-Aventis and Caris Life Sciences. More than 25 years of experience in the Life Sciences & Biotechnology industry at national and international levels (Germany, France, Austria, Greece, Israel, Republic of South Africa). Focus on (ultra) rare diseases & oncology. Expertise in strategic & operational marketing, market access and P&R. Educated as a pharmacist, holds a Master’s Degree in Marketing, graduated from INSEAD Marketing Champions Program.